株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ムコ多糖症VI型:主要30ヶ国の市場予測 (2018~2028年)

Epiomic Epidemiology Series: Mucopolysaccharidosis Type VI Forecast in 30 Major Markets 2018-2028

発行 Black Swan Analysis 商品コード 660256
出版日 ページ情報 英文 86 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.80円で換算しております。
Back to Top
ムコ多糖症VI型:主要30ヶ国の市場予測 (2018~2028年) Epiomic Epidemiology Series: Mucopolysaccharidosis Type VI Forecast in 30 Major Markets 2018-2028
出版日: 2018年07月01日 ページ情報: 英文 86 Pages
概要

当レポートでは、世界の主要30ヶ国におけるムコ多糖症VI型の発症状況について分析し、疾患の概要や現時点での有病者数、性別・年代別の詳細状況、地域別・民族別傾向、リスク要因、疾患の診断と予後、主な症状や合併症、将来的な動向見通し (今後10年間分) といった情報を取りまとめてお届けいたします。

目次

  • 図表一覧
  • イントロダクション
  • 疾患の原因
  • 危険因子と予防法
  • 疾患の診断
  • 地域別/民族別の差異
  • 疾患の予後と臨床経過
  • 疾患に関連する主な併存症/特徴
  • 患者数の定量化の手法
  • ムコ多糖症VI型の最大有病者数
  • ムコ多糖症VI型の特徴
  • ムコ多糖症VI型の主な併存症
  • 略語
  • その他のBLACK SWAN のサービス & ソリューション
  • レポート・出版物
  • オンラインデータベース:疫学
  • オンラインデータベース:薬価
  • 参考文献
  • 付録

調査対象国一覧

  • 米国、カナダ、フランス、ドイツ、イタリア、スペイン、英国、ポーランド、オランダ、ベルギー、ノルウェー、スウェーデン、デンマーク、オーストリア、スイス、ポルトガル、チェコ共和国、リトアニア、エストニア、ロシア、トルコ、サウジアラビア、日本、中国、韓国、インド、オーストラリア、ブラジル、メキシコ、アルゼンチン
目次
Product Code: MPS60010718

Black Swan Analysis Epiomic™ Epidemiology Forecast Report on Mucopolysaccharidosis Type VI in 30 Major Markets

Mucopolysaccharidosis type VI (MPS VI), also known as Maroteaux-Lamy syndrome, is an inherited autosomal recessive genetic disorder in which glycosaminoglycans (GAGs) are accumulated in lysosomes due to mutations that cause loss of function of an enzyme responsible for degrading GAGs. The disorder manifests with a broad spectrum of possible clinical presentations, with skeletal deformities, neurological complications and cardiac dysfunction being most common. MPS VI constitutes a burden to the patients and their families as the disease progresses and the patients develop mobility impairment, heart problems and corneal clouding.

This report provides the current prevalent population for MPS VI across 30 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Norway, Sweden, Denmark, Austria, Switzerland, Portugal, Czech Republic, Lithuania, Estonia, Russia, Turkey, Saudi Arabia, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, MPS VI patients grouped by disease severity and comorbidities have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities of MPS VI include:

  • Cardiac valvular dysfunction
  • Heart failure
  • Recurrent airway (pneumonia, sinusitis) and ear (otitis media) infections
  • Respiratory failure
  • Obstructive sleep apnoea
  • Pulmonary hypertension
  • Joint disease
  • Cervical spine compression
  • Hydrocephalus
  • Glaucoma
  • Deafness
  • Umbilical and inguinal hernia

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

Ability to quantify patient populations in global MPS VI market to target the development of future products, pricing strategies and launch plans.

Further insight into the prevalence of the subdivided types of MPS VI and identification of patient segments with high potential.

Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

Better understanding of the impact of specific co-morbid conditions on the prevalent population of MPS VI patients.

Identification of MPS VI patient sub-populations that require treatment.

Better understanding of the specific markets that have the largest number of MPS VI patients.

Table of Contents

  • LIST OF TABLES AND FIGURES
  • INTRODUCTION
  • CAUSE OF THE DISEASE
  • RISK FACTORS & PREVENTION
  • DIAGNOSIS OF THE DISEASE
  • VARIATION BY GEOGRAPHY/ETHNICITY
  • DISEASE PROGNOSIS & CLINICAL COURSE
  • KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
  • METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
  • TOP-LINE PREVALENCE FOR MUCOPOLYSACCHARIDOSIS TYPE VI
  • FEATURES OF MUCOPOLYSACCHARIDOSIS TYPE VI PATIENTS
  • COMORBIDITIES OF MUCOPOLYSACCHARIDOSIS TYPE VI PATIENTS
  • ABBREVIATIONS USED IN THE REPORT
  • OTHER BLACK SWAN SERVICES & SOLUTIONS
  • REPORTS & PUBLICATIONS
  • ONLINE EPIDEMIOLOGY DATABASES
  • ONLINE PHARMACEUTICAL PRICING DATABASE
  • REFERENCES
  • APPENDIX

LIST OF TABLES AND FIGURES

  • Table 1. Characteristics of the three subtypes of MPS VI
  • Table 2. Prevalence of MPS VI, total (000s)
  • Table 3. Prevalence of MPS VI, males (000s)
  • Table 4. Prevalence of MPS VI, females (000s)
  • Table 5. Patients with MPS VI by severity, total (000s)
  • Table 6. MPS VI patients with aortic regurgitation, total (000s)
  • Table 7. MPS VI patients with mitral regurgitation, total (000s)
  • Table 8. MPS VI patients with pulmonary regurgitation, total (000s)
  • Table 9. MPS VI patients with mitral valve stenosis, total (000s)
  • Table 10. MPS VI patients with aortic valve stenosis, total (000s)
  • Table 11. Abbreviations and acronyms used in the report
  • Table 12. USA prevalence of MPS VI by 5-yr age cohort, males (000s)
  • Table 13. USA prevalence of MPS VI by 5-yr age cohort, females (000s)
  • Table 14. Canada prevalence of MPS VI by 5-yr age cohort, males (000s)
  • Table 15. Canada prevalence of MPS VI by 5-yr age cohort, females (000s)
  • Table 16. France prevalence of MPS VI by 5-yr age cohort, males (000s)
  • Table 17. France prevalence of MPS VI by 5-yr age cohort, females (000s)
  • Table 18. Germany prevalence of MPS VI by 5-yr age cohort, males (000s)
  • Table 19. Germany prevalence of MPS VI by 5-yr age cohort, females (000s)
  • Table 20. Italy prevalence of MPS VI by 5-yr age cohort, males (000s)
  • Table 21. Italy prevalence of MPS VI by 5-yr age cohort, females (000s)
  • Table 22. Spain prevalence of MPS VI by 5-yr age cohort, males (000s)
  • Table 23. Spain prevalence of MPS VI by 5-yr age cohort, females (000s)
  • Table 24. UK prevalence of MPS VI by 5-yr age cohort, males (000s)
  • Table 25. UK prevalence of MPS VI by 5-yr age cohort, females (000s)
  • Table 26. Poland prevalence of MPS VI by 5-yr age cohort, males (000s)
  • Table 27. Poland prevalence of MPS VI by 5-yr age cohort, females (000s)
  • Table 28. Netherlands prevalence of MPS VI by 5-yr age cohort, males (000s)
  • Table 29. Netherlands prevalence of MPS VI by 5-yr age cohort, females (000s)
  • Table 30. Belgium prevalence of MPS VI by 5-yr age cohort, males (000s)
  • Table 31. Belgium prevalence of MPS VI by 5-yr age cohort, females (000s)
  • Table 32. Norway prevalence of MPS VI by 5-yr age cohort, males (000s)
  • Table 33. Norway prevalence of MPS VI by 5-yr age cohort, females (000s)
  • Table 34. Sweden prevalence of MPS VI by 5-yr age cohort, males (000s)
  • Table 35. Sweden prevalence of MPS VI by 5-yr age cohort, females (000s)
  • Table 36. Denmark prevalence of MPS VI by 5-yr age cohort, males (000s)
  • Table 37. Denmark prevalence of MPS VI by 5-yr age cohort, females (000s)
  • Table 38. Austria prevalence of MPS VI by 5-yr age cohort, males (000s)
  • Table 39. Austria prevalence of MPS VI by 5-yr age cohort, females (000s)
  • Table 40. Switzerland prevalence of MPS VI by 5-yr age cohort, males (000s)
  • Table 41. Switzerland prevalence of MPS VI by 5-yr age cohort, females (000s)
  • Table 42. Portugal prevalence of MPS VI by 5-yr age cohort, males (000s)
  • Table 43. Portugal prevalence of MPS VI by 5-yr age cohort, females (000s)
  • Table 44. Czech Republic prevalence of MPS VI by 5-yr age cohort, males (000s)
  • Table 45. Czech Republic prevalence of MPS VI by 5-yr age cohort, females (000s)
  • Table 46. Lithuania prevalence of MPS VI by 5-yr age cohort, males (000s)
  • Table 47. Lithuania prevalence of MPS VI by 5-yr age cohort, females (000s)
  • Table 48. Estonia prevalence of MPS VI by 5-yr age cohort, males (000s)
  • Table 49. Estonia prevalence of MPS VI by 5-yr age cohort, females (000s)
  • Table 50. Russia prevalence of MPS VI by 5-yr age cohort, males (000s)
  • Table 51. Russia prevalence of MPS VI by 5-yr age cohort, females (000s)
  • Table 52. Turkey prevalence of MPS VI by 5-yr age cohort, males (000s)
  • Table 53. Turkey prevalence of MPS VI by 5-yr age cohort, females (000s)
  • Table 54. Saudi Arabia prevalence of MPS VI by 5-yr age cohort, males (000s)
  • Table 55. Saudi Arabia prevalence of MPS VI by 5-yr age cohort, females (000s)
  • Table 56. Japan prevalence of MPS VI by 5-yr age cohort, males (000s)
  • Table 57. Japan prevalence of MPS VI by 5-yr age cohort, females (000s)
  • Table 58. China prevalence of MPS VI by 5-yr age cohort, males (000s)
  • Table 59. China prevalence of MPS VI by 5-yr age cohort, females (000s)
  • Table 60. South Korea prevalence of MPS VI by 5-yr age cohort, males (000s)
  • Table 61. South Korea prevalence of MPS VI by 5-yr age cohort, females (000s)
  • Table 62. India prevalence of MPS VI by 5-yr age cohort, males (000s)
  • Table 63. India prevalence of MPS VI by 5-yr age cohort, females (000s)
  • Table 64. Australia prevalence of MPS VI by 5-yr age cohort, males (000s)
  • Table 65. Australia prevalence of MPS VI by 5-yr age cohort, females (000s)
  • Table 66. Brazil prevalence of MPS VI by 5-yr age cohort, males (000s)
  • Table 67. Brazil prevalence of MPS VI by 5-yr age cohort, females (000s)
  • Table 68. Mexico prevalence of MPS VI by 5-yr age cohort, males (000s)
  • Table 69. Mexico prevalence of MPS VI by 5-yr age cohort, females (000s)
  • Table 70. Argentina prevalence of MPS VI by 5-yr age cohort, males (000s)
  • Table 71. Argentina prevalence of MPS VI by 5-yr age cohort, females (000s)
Back to Top